Androgenic Alopecia Treatment
More news is coming out of Kintor Pharma this month. Kintor Pharma (HKEX: 9939) has announced that its observational study evaluating the combination of KX-826 and minoxidil for the treatment of androgenetic alopecia (AGA) in adult males in China has successfully reached its primary endpoint. This marks another milestone in the development of KX-826, following…
Read More
Atticus Pharma, a clinical-stage biopharmaceutical company specializing in immunodermatology treatments, has announced the initiation of its first human clinical trial of ATC-002 for androgenic alopecia. What is Atticus Pharma? Atticus Pharma was founded in 2024 to develop pharmaceutical applications of its proprietary Z-pod® technology, a sustained-release drug delivery platform designed to improve treatment outcomes in…
Read More
There is more news in the androgenic alopecia space, as Eirion Therapeutics begins a Phase 1 trial for ET-02, a topical treatment. What is ET-02? According to Eirion Therapeutics, ET-02 works by targeting hair follicle stem cells that have become defective or inactive in individuals suffering from androgenic alopecia, enabling hair follicles to resume normal…
Read More
Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il Messaggero, quote “The most curious thing is that the currently candidate drug,…
Read More
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read More
Published on: Oct 7, 2020 at 20:04
Read More
An overview of treatments for pattern baldness and alopecia which will be in the clinical trial stage during 2023. Androgenetic Alopecia Trials Chong Kun Dang Pharmaceutical – We begin the list with a newcomer, previously unannounced. CKD-843 is a new injectable drug being trialed in “alopecia” by the Chong Kun Dang (CKD) Pharmaceutical company of Seoul,…
Read More
US Male Phase 2 Pyrilutamide Trial Underway: Update (3/1/22) Consistent progress is the M.O. of Kintor Pharma. On March 1, 2022 it was announced that the first patients in a US phase 2 trial for males have received dosing. The four cohorts in the trial will receive topical dosing of either 2.5 mg pyrilutamide twice…
Read MoreHello everyone, and welcome to another edition of Weekly Thoughts. It has been a little while since my last check in with you all. You can chalk it up to a busy schedule and the fact that there hasn’t been too much significant news in the hair growth treatment world recently. As always, there are…
Read More
The times they are a-changing. Nowadays you can’t even take a trip to the fridge to grab more hummus dip without some hair growth startup rolling out their new website and business plan. Jokes aside, Follica has been the ultimate tight-lipped company in the hair regeneration biz for about 8 years now. To be honest,…
Read More